COSCIENS ANNOUNCES NEW CORPORATE PRESENTATION AND PROVIDES UPDATE ON CONVERTIBLE DEBENTURE OFFERING
Financial Post ·
TORONTO, ONTARIO, Oct. 19, 2026 (GLOBE NEWSWIRE) — COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) (“COSCIENS” or the “Company”) is pleased to announce the publication of a new corporate presentation, now available on its website at www.cosciensbio.com. The presentation provides an overview of the Company and its operating subsidiaries, following the recent acquisition of Nualtis […]
Certain statements in this news release constitute “forward-looking statements” and/or “forward-looking information” under applicable securities laws. All statements, other than statements of historical fact, that address circumstances, events, activities, or developments that could or may or will occur are forward-looking statements. When used in this news release, words such as “anticipate”, “assume”, “believe”, “could”, “expect”, “forecast”, “future”, “goal”, “guidance”, “intend”, “likely”, “may”, “would” or the negative or comparable terminology as well as terms usually used in the future and the conditional are generally intended to identify forward-looking statements, although not all forward-looking statements include such words. Specific forward-looking statements in this document include, but are not limited to, statements relating to: expectations related to additional sales under the Offering and the pro forma market capitalization and cash position of the Company. All forward-looking statements are given pursuant to the “safe harbour” provisions of applicable securities legislation. Read More